Clinical Trial Update: HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for HLX301, a TIGIT×PDL1 bispecific, in locally advanced or metastatic solid tumors and non-small cell lung cancer across Phase 1 and Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Or Metastatic Solid Tumors

Drugs mentioned

• HLX301 (TIGIT×PD-L1 bispecific)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN